TrialsTrialsTrials

 Schizophrenia Battery

The MATRICS Initiative

As a result of an agreement between the FDA and NIH that cognitive dysfunction/impairment is an important health issue in schizophrenia, the FDA confirmed that improved cognitive function would be considered as a primary outcome in schizophrenia research. Following this guidance, the MATRICS initiative (a collaboration of the FDA, NIH, academic researchers and industry), recommended a test battery for the assessment of cognition in people with schizophrenia.

Prior to the MATRICS initiative, there was no consensus on the optimum outcome measures for evaluation of cognitive function in clinical trials in schizophrenia. The test criteria recommended by the MATRICS group was defined as:

The MATRICS initiative also recommended the cognitive domains to be tested in order to assess cognitive function in schizophrenic patients. This is illustrated in the table below.

The CogState Scizophrenia Battery

 Domain

 MATRICS test

Equivalent CogState task
 

Speed of Processing

Category Fluency / Symbol Coding

Detection Task

Attention / Vigilance

Continuous Performance Task

Identification Task

Working Memory

Verbal Span / Spatial Span

One-Back / Two-Back Task

Visual Learning

Object Learning

One Card Learning Task

Verbal Learning

Word List Learning

International Shopping List Task

Reasoning / Problem Solving

Mazes

Groton Maze Learning Task

Social Cognition

Managing Emotions Test

Social-Emotional Cognition Task

CogState's Schizophrenia Battery was developed with all the MATRICS criteria and recommendations in mind. All CogState tasks have been developed to meet the criteria set out above with regards to scientific validity, reliability and consistency and we have selected a set of tasks that target those cognitive domains recommended by the MATRICS initiative. 

The benefits of the CogState Schizophrenia Battery


 

Contact